Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?

Worldwide, there is a shifting paradigm from immediate surgery with adjuvant treatment to a neoadjuvant approach for patients with resectable or borderline resectable pancreatic cancer (RPC or BRPC). Comparison of neoadjuvant and adjuvant studies is extremely difficult because of a great difference...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Eva Versteijne, Ignace H. J. T. de Hingh, Marjolein Y. V. Homs, Martijn P. W. Intven, Joost M. Klaase, Hjalmar C. van Santvoort, Judith de Vos-Geelen, Johanna W. Wilmink, Geertjan van Tienhoven
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2022-02-01
Serija:	Frontiers in Oncology
Teme:	resectable pancreatic cancer (RPC) borderline resectable pancreatic cancer (BRPC) chemotherapy radiotherapy neoadjuvant treatment
Online dostop:	https://www.frontiersin.org/articles/10.3389/fonc.2021.744161/full
Oznake:	Označite Brez oznak, prvi označite!